The NF-κB/Rel signaling system is a paradigm for gene activation in response to inflammatory and menacing stimuli. Given the growing body of evidence showing an important involvement of NF-κB for the onset of autoimmune diseases and different types of cancer, NF-κB is an important drug target for the adjuvant therapy of these diseases. Great efforts have been made for the development of highly specific NF-κB inhibitors, some of them being currently tested in phase II clinical trials. Here we discuss recent progress in the identification of druggable components of the NF- κB signaling system and the development and potential use of novel NF-κB inhibitors.
A battery of proinflammatory agents triggers the activation of NF-κB. This inducible transcription factor participates in the expression of an exceptionally large number of target genes, many of them contributing to the regulation of innate and adaptive immunity. Since some target genes also function as NF-κB activators, activation of this transcription factor allows the establishment of a signal amplification loop. Dysregulation of the NF-κB system and hyperactivated expression of inflammatory mediators are often found in association with some autoimmune diseases, which occur upon mounting of the adaptive immune response against self-antigens. In this review we summarize the relevance of aberrant NF-κB signaling for the development and perpetuation of some autoimmune diseases such as rheumatoid arthritis, diabetes mellitus type 1 and Crohns disease. The assets and drawbacks of systemic or cell-type specific NF-kB inhibitors and their potential use in therapy of autoimmune diseases are critically discussed.
NF-κB is a transcription factor involved in immune and inflammatory responses. Here we show that micromolar concentrations of hypericin inhibited the PMA- and TNF-α-induced activation of NF-κB in HeLa and TC10 cells, respectively. In contrast, NF-κB activated by H2O2 was not influenced by hypericin, indicating a pathway-specificity of hypericin. Hyperforin and a HYPERICUM PERFORATUM extract standardised on 0.15% hypericin and 5% hyperforin were not active at pharmacologically relevant concentrations. The PMA/TNF-α-induced transcription of a reporter gene, which is under the control of the NF-κB-dependent IL-6 promoter, was strongly reduced by preincubation with hypericin.